These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 28203071

  • 1. Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD.
    Bishwakarma R, Zhang W, Kuo YF, Sharma G.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():477-486. PubMed ID: 28203071
    [Abstract] [Full Text] [Related]

  • 2. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N.
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [Abstract] [Full Text] [Related]

  • 3. Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators.
    Keshishian A, Xie L, Dembek C, Yuce H.
    Clin Ther; 2019 Nov; 41(11):2283-2296. PubMed ID: 31630815
    [Abstract] [Full Text] [Related]

  • 4. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V, Corhay JL, Germonpré P, Janssens W, Joos GF, Liistro G, Vincken W, Gurdain S, Vanvlasselaer E, Lehouck A.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov; 12():793-801. PubMed ID: 28293106
    [Abstract] [Full Text] [Related]

  • 5. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov; 13():781-792. PubMed ID: 29551894
    [Abstract] [Full Text] [Related]

  • 6. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC, Fairbrother SE, Scowcroft A, Chiu G, Ternouth A, Lipworth BJ.
    Int J Chron Obstruct Pulmon Dis; 2016 Nov; 11():2851-2858. PubMed ID: 27920512
    [Abstract] [Full Text] [Related]

  • 7. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
    Celli BR, Navaie M, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov; 14():1019-1031. PubMed ID: 31190787
    [Abstract] [Full Text] [Related]

  • 8. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 9. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A, Montes de Oca M, Menezes AM, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov; 13():1545-1556. PubMed ID: 29785104
    [Abstract] [Full Text] [Related]

  • 10. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov; 12():907-922. PubMed ID: 28360514
    [Abstract] [Full Text] [Related]

  • 11. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
    Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS.
    Int J Chron Obstruct Pulmon Dis; 2013 Nov; 8():631-9. PubMed ID: 24353413
    [Abstract] [Full Text] [Related]

  • 12. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
    Meeraus W, Wood R, Jakubanis R, Holbrook T, Bizouard G, Despres J, Silva CCD, Nachbaur G, Landis SH, Punekar Y, Aguilaniu B, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov; 14():51-63. PubMed ID: 30587961
    [Abstract] [Full Text] [Related]

  • 13. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
    Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov; 13():1229-1237. PubMed ID: 29713156
    [Abstract] [Full Text] [Related]

  • 14. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
    Mannino DM, Clerisme-Beaty EM, Franceschina J, Ting N, Leidy NK.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov; 13():1515-1525. PubMed ID: 29785101
    [Abstract] [Full Text] [Related]

  • 15. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

  • 16. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
    Simeone JC, Luthra R, Kaila S, Pan X, Bhagnani TD, Liu J, Wilcox TK.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr; 12():73-83. PubMed ID: 28053518
    [Abstract] [Full Text] [Related]

  • 17. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC, Chen CH, Lin CYH, Wang CY, Wang YH.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr; 14():1539-1548. PubMed ID: 31371939
    [Abstract] [Full Text] [Related]

  • 18. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
    Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr; 14():531-546. PubMed ID: 30880943
    [Abstract] [Full Text] [Related]

  • 19. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
    Singer D, Bengtson LGS, Elliott C, Buikema AR, Franchino-Elder J.
    Int J Chron Obstruct Pulmon Dis; 2020 Apr; 15():3239-3250. PubMed ID: 33324047
    [Abstract] [Full Text] [Related]

  • 20. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.
    Int J Chron Obstruct Pulmon Dis; 2018 Apr; 13():3971-3981. PubMed ID: 30587953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.